Resource Summary Report

Generated by RRID on Jul 31, 2026

APC anti-human CD3

RRID:AB_1937212
Type: Antibody

Proper Citation

BioLegend Cat# 317318, RRID:AB_1937212

Antibody Information

URL: http://antibodyregistry.org/AB_1937212

Proper Citation: BioLegend Cat# 317318, RRID:AB_1937212

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_1937212

Vendor: BioLegend

Catalog Number: 317318

Alternative Catalog Numbers: 317317

Record Creation Time: 20250820T033130+0000

Record Last Update: 20250820T162909+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community. Contact(s): Jing Chen, Mark Atkinson, Todd Brusko, Clayton Mathews - Human Islets Research Network https://hirnetwork.org/

No alerts have been found for APC anti-human CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell.

Schiantarelli J, et al. (2025) Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. Cancer cell, 43(2), 308.

Geilenkeuser J, et al. (2025) Engineered nucleocytosolic vehicles for loading of programmable editors. Cell, 188(10), 2637.

Wang S, et al. (2024) Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. Cancer research.

Abdelfattah NS, et al. (2024) T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics. Immunity, 57(12), 2945.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. iScience, 27(1), 108597.

Quiros-Fernandez I, et al. (2024) Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. Journal of medical virology, 96(5), e29630.

Pan Q, et al. (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A?02:01 patients with advanced soft tissue sarcoma. Cell reports. Medicine, 4(8), 101133.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell reports. Medicine, 4(2), 100917.

Wu G, et al. (2023) Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. Frontiers in immunology, 14, 1093750.

Long J, et al. (2023) A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. Cell reports. Medicine, 4(11), 101286.

Wang C, et al. (2023) Dysregulated lung stroma drives emphysema exacerbation by potentiating resident lymphocytes to suppress an epithelial stem cell reservoir. Immunity, 56(3), 576.

Nelde A, et al. (2023) Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood cancer discovery, 4(6), 468.

Zhang Z, et al. (2022) A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer cell, 40(9), 1060.

Alam A, et al. (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer cell, 40(2), 153.

Qian Y, et al. (2021) ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. Cell reports, 36(8), 109602.